Everything below concerns Peptidomimetic. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
== Laboratory measurement == The reference range for prothrombin time depends on the analytical method used, but is usually around 12–13 seconds (results should always be interpreted using the reference range from the laboratory that performed the test), and the INR in absence of anticoagulation therapy is 0.8–1.2. The target range for INR in anticoagulant use (e.g. warfarin) is 2 to 3. In some cases, if more intense anticoagulation is thought to be required, the target range may be as high as 2.5–3.5 depending on the indication for anticoagulation.
=== Rum trading === Grose also relaxed Phillip's prohibition on trading of rum, sometimes a generic term for any form of distilled beverage, usually made from wheat, commonly from Bengal. The colony, like many British territories at the time, was short of coins, and rum soon became the medium of trade. The officers of the Corps were able to use their position and wealth to buy all the imported rum and then exchange it for goods and labour at very favourable rates, earning the Corps the nickname "The Rum Corps". By 1793 stills were being imported and grain was being used to make rum, exacerbating the shortage of grain. Due to poor health Grose returned to England in December 1794 and Captain William Paterson assumed temporary command until a permanent replacement, Governor John Hunter, arrived in September 1795. Paterson had obtained his commission with the backing of Sir Joseph Banks because he was interested in natural history and would explore and collect samples for Banks and the Royal Society. Governor Hunter attempted unsuccessfully to use the troops of the Corps to guard imported rum and stop the officers from buying it up. Attempts to stop the importation were also thwarted by the failure of other governments to co-operate and by the Corps' officers chartering of a Danish ship to bring in a large shipment of rum from India. Hunter also tried to start up a public store with goods from England to provide competition and stabilise the price of goods, but Hunter was not a good businessman and supplies were too erratic.
Rather, the tRNA-bound seryl residue is converted to a selenocysteine residue by the pyridoxal phosphate-containing enzyme selenocysteine synthase. In eukaryotes and archaea, two enzymes are required to convert tRNA-bound seryl residue into tRNA selenocysteinyl residue: PSTK (O-phosphoseryl-tRNA[Ser]Sec kinase) and selenocysteine synthase. Finally, the resulting Sec-tRNASecis specifically bound to an alternative translational elongation factor (SelB or mSelB (or eEFSec)), which delivers it in a targeted manner to the ribosomes translating mRNAs for selenoproteins. The specificity of this delivery mechanism is brought about by the presence of an extra protein domain (in bacteria, SelB) or an extra subunit (SBP2 for eukaryotic mSelB/eEFSec) which bind to the corresponding RNA secondary structures formed by the SECIS elements in selenoprotein mRNAs.
=== Matrix === The matrix system has a drug layer of a semisolid matrix containing a drug solution or suspension. The adhesive layer in this patch surrounds the drug layer, partially overlaying it. The release rate is determined by the physical properties of the matrix. Also known as a monolithic device. Limited research indicates that it may be possible to cut some matrix patches to provide lower doses, provided the cut part not immediately used is stored at cool temperatures.
May 2011 - Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum ) Sept 2010 - Highly Multiparametric Analysis by Mass Cytometry Aug 2009 - Mass Cytometry: Technique for Real Time Single Cell Multitarget Immunoassay Based on Inductively Coupled Plasma Time-Of-Flight Mass Spectrometry Sept 2002 - Reaction Cells and Collision Cells for ICP-MS: A Tutorial Review April 2002 - A Sensitive and Quantitative Element-Tagged Immunoassay with ICPMS Detection April 2002 - Detection of Ultratrace Phosphorus and Sulfur by Quadrupole ICPMS with Dynamic Reaction Cell July 2001 - Reaction Chemistry and Collisional Processes in Multipole Devices for Resolving Isobaric Interferences in ICP–MS Aug 2000 - A Dynamic Reaction Cell for Inductively Coupled Plasma Mass Spectrometry (ICP-DRC-MS). Part III. Nov 1999 - A Dynamic Reaction Cell for Inductively Coupled Plasma Mass Spectrometry (ICP-DRC-MS). Part II. Reduction of Interferences Produced within the Cell March 1999 - Theory, Design, and Operation of a Dynamic Reaction Cell for ICP-MS Jan 1995 - Characterization of Ionization and Matrix Suppression in Inductively Coupled ‘Cold’ Plasma Mass Spectrometry June 1992 - Space Charge in ICP-MS: Calculation and Implications July 1988 - Nonspectroscopic Interelement Interferences in Inductively Coupled Plasma Mass Spectrometry A more complete listing of his publications can be found on Google Scholar
Sources: en.wikipedia.org
== History == LG CNS was founded in 1987 as System Technology Management (STM), a 50:50 joint venture between LG and Electronic Data Systems. In 1995, the company was renamed LG-EDS System as part of LG Group's corporate identity integration project. After LG acquired all of EDS's shares, the company changed its name to LG CNS in January 2002. In 2019, LG sold a 35% stake in LG CNS to Macquarie Group for 1 trillion won (US$865 million). This sale occurred amid growing criticism of South Korea's chaebols for allegedly benefiting founding families by over-relying on outsourcing contracts and directing work to subsidiaries and affiliates. Macquarie acquired the stake in LG CNS with the condition that LG would list the company by April 2025. As a result, LG CNS debuted on the market in February 2025. On January 28, 2026, Macquarie divested its remaining 8.3% stake in the company through a block deal.
== Other use of sake kasu == Sake kasu can be found in different cosmetics and skincare products such as facial masks, bath powder, and face cream. There is an old folktale about an elderly man who worked in a brewery with youthful-looking hands compare to his old wrinkled face; in light of this, different cosmetics companies use sake kasu as an ingredient and a selling point for their product. A research scientist found an old sake brewer who had no wrinkles on his hands due to the constant contact with the yeast produced during the sake fermentation process. Other research focused on the yeast produced during the sake fermentation process leading to a product line called Pitera. Sake kasu can also be used as the main ingredient for homemade beauty products including sake kasu facial masks and body masks. Adding citrus fruit juice, honey, and rice water, aloe vera or rose water to sake kasu can create a mask for both face and body. It brightens the users' skin and the antioxidants in the mask can stimulate collagen production. Because sake kasu contains alcohol, it is recommended that sunscreen be applied before using the homemade sake kasu mask. Sake kasu can be beneficial for cosmetic use due to the high amount of triacylglycerols found in freeze-dried sake kazu. Tyrosinase catalytic activity is hindered by the n-hexane extract from freeze-dried sake kasu. Tyrosinase inhibitor was further purified by the n-hexane extract from the freeze-dried sake kasu.
Wagyu (Japanese: 和牛, Hepburn: wagyū, lit. 'Japanese cattle') is not the name of a single cattle breed. Today, the term usually refers to four established Japanese breeds of beef cattle: the Japanese Black, Japanese Brown, Japanese Polled, and Japanese Shorthorn. Historically, it was also used for native Japanese cattle; the surviving Mishima and Kuchinoshima cattle populations are not included among the four modern breeds. Beginning in the late nineteenth century, these breeds were developed from regional native cattle crossed with imported stock. The timing of crossbreeding and the imported breeds involved varied by breed and region. The resulting cattle were later established as distinct breeds through selection and closed breeding. The Japanese Black accounts for more than 90% of Wagyu cattle raised in Japan and is the main source of the highly marbled beef commonly associated with Wagyu. Its beef has finely distributed intramuscular fat known as sashi, a high proportion of monounsaturated fatty acids, and a distinctive sweet aroma that develops during cooking. The other three breeds generally produce less heavily marbled beef. Regional names such as Kobe beef, Matsusaka beef, Ōmi beef, and Yonezawa beef refer to brands defined by geographical origin and production or quality standards, not to additional cattle breeds. In Japan, beef carcasses are graded separately for meat yield and meat quality.
==== Thymomas ==== Tumours originating from the thymic epithelial cells are called thymomas. They most often occur in adults older than 40. Tumours are generally detected when they cause symptoms, such as a neck mass or affecting nearby structures such as the superior vena cava; detected because of screening in patients with myasthenia gravis, which has a strong association with thymomas and hyperplasia; and detected as an incidental finding on imaging such as chest X-rays. Hyperplasia and tumours originating from the thymus are associated with other autoimmune diseases – such as hypogammaglobulinemia, Graves disease, pure red cell aplasia, pernicious anaemia and dermatomyositis, likely because of defects in negative selection in proliferating T cells. Thymomas can be benign; benign but by virtue of expansion, invading beyond the capsule of the thymus ("invasive thymoma"), or malignant (a carcinoma). This classification is based on the appearance of the cells. A WHO classification also exists but is not used as part of standard clinical practice. Benign tumours confined to the thymus are most common, followed by locally invasive tumours, and then by carcinomas. There is variation in reporting, with some sources reporting malignant tumours as more common. Invasive tumours, although not technically malignant, can still spread (metastasise) to other areas of the body. Even though thymomas originate from epithelial cells, they can also contain thymocytes. Treatment of thymomas often requires surgery to remove the entire thymus.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.